Skip to main content

Providing independent clinical excellence since 2005

The SCVC Blog

Cardiovascular care news and articles from our expert team

What the heck is LP (a)?

Posted on Wednesday April 24, 2024 in Metabolic Health

An article by Dr Edward Leatham, Consultant Cardiologist

In the realm of cardiovascular health, awareness about cholesterol levels and their effects on the body is relatively widespread. However, a specific type of lipoprotein known as Lipoprotein(a), LPA or Lp(a) remains underexplored and underappreciated, despite its significant implications for coronary heart disease (CHD). This article highlights the defect that explains why people who inherit the gene coding for high LP (a) may be at greater risk of heart attacks or strokes, even if they appear perfectly healthy, with the objective of raising awareness of the emerging role of Lp(a) as an important cardiovascular risk factor, that may be worth measuring.

The Underappreciated Lp(a)

While most are familiar with low-density lipoprotein (LDL) or “bad” cholesterol, fewer are aware of the dangers posed by Lp(a). Research indicates that up to 20% of the global population might have elevated levels of Lp(a), significantly increasing their risk of heart attacks and other severe cardiac events. Lp(a) consists of LDL cholesterol linked to a protein called apolipoprotein(a), which makes it more likely to cause arterial blockages and clots.

Despite its role, Lp(a) is seldom measured in routine checks and often goes unnoticed by even the most diligent cardiologists, mainly due to its complex nature and the limited treatment options currently available. Within a few months of including the LP (a) test as part of our metabolic health assessment for patients with high FAI scores (indicating much higher risk of fatal coronary events within 8 years) undergoing an individualised approach to CHD prevention, we have discovered numerous patients have high LP(a): another poignant example of the old saying that ‘the more you look, the more you will find’.

How does LP(a) cause health issues?

Promotes Atherosclerosis

The first and perhaps the most well-understood mechanism is through its similarity to other apolipoprotein B (ApoB)-containing lipoproteins. Like LDL and other members of the ApoB family, Lp(a) can penetrate the arterial wall. Once inside, it promotes inflammatory reactions, a pivotal step in the pathogenesis of atherosclerosis. The presence of Lp(a) in the arterial wall facilitates the accumulation of lipids and inflammatory cells, leading to plaque formation. These plaques can progressively narrow the arteries, reduce blood flow, or rupture, leading to serious cardiovascular events such as heart attacks and strokes.

Carriage of Oxidized Phospholipids (OxPLs)

Lp(a) is also a significant carrier of oxidized phospholipids (OxPLs), which have been directly implicated in the development of cardiovascular disease. Studies have shown that blood levels of OxPLs are strongly associated with the risk of atherosclerotic disease. OxPLs contribute to the atherogenic process by promoting inflammation, endothelial dysfunction, and further oxidative damage within the arterial wall. Additionally, OxPLs carried by Lp(a) have been associated with an increased risk of calcified aortic valve stenosis, highlighting another pathway through which Lp(a) may lead to cardiovascular complications.

Interaction with Plasminogen

The unique structure of Lp(a), especially the apolipoprotein(a) component, bears a striking resemblance to plasminogen, an enzyme crucial for the dissolution of blood clots. This structural similarity suggests that Lp(a) might competitively inhibit the function of plasminogen. By interfering with the natural fibrinolytic (clot-dissolving) process, high levels of Lp(a) could potentially increase the risk of thrombosis, further complicating its role in heart disease. This mechanism suggests a dual threat posed by Lp(a) – not only does it contribute to atherosclerosis, but it may also exacerbate the risk of acute thrombotic events.

Lp(a) as an Independent Risk Factor

Historically, Lp(a) was only considered a concern in conjunction with other cardiovascular risk factors. However, it is now recognized as an independent risk factor for heart disease, affecting even young, seemingly healthy individuals. High-profile cases, such as Emmy-Award-nominated actress Marin Hinkle and Sandra Tremulis, founder of the Lipoprotein(a) Foundation, who discovered a 95% blockage at age 39, highlight the insidious nature of high Lp(a) levels.

The Genetic Component

The level of Lp(a) in individuals is primarily determined by genetics, specifically the LPA gene. This makes traditional preventive strategies like diet and exercise ineffective in reducing Lp(a) levels. It also underlines the importance of genetic factors over lifestyle in managing this risk factor. Further complicating matters are the racial disparities in Lp(a) levels, with Black individuals generally having higher levels than other races, necessitating more research into the role of genetics and ethnicity.

The Hidden Impact on LDL-C Levels

Interestingly, Lp(a) can significantly impact the overall levels of LDL cholesterol measured during standard blood tests. For instance, individuals with high Lp(a) might show deceptively high LDL-C levels, which could skew their cardiovascular risk profile if Lp(a) is not separately measured. This makes Lp(a) testing worthwhile, particularly for those who continue to experience cardiovascular events despite having controlled LDL levels.

Knowing Your Lp(a) Number

Understanding your Lp(a) level is important for a comprehensive assessment of cardiovascular risk. This lipoprotein can carry a substantial portion of your LDL cholesterol, potentially increasing your risk of heart disease and stroke beyond what standard cholesterol tests might suggest. Lp(a) testing is therefore advised for individuals at high risk for cardiovascular disease, including those with a prior stent or bypass operation, coronary syndrome or heart attack as well as anyone with a family history of coronary heart disease, high FAI (coronary inflammation) or high risk patterns on Cardiac CT angiograms.  In our practice, Lp (a) is offered as part of our comprehensive  Metabolic Health assessment (MHA1).

Here’s how Lp(a) levels are typically categorized in terms of cardiovascular risk:

  • Desirable: < 14 mg/dL (< 35 nmol/l)
  • Borderline risk: 14 – 30 mg/dL (35 – 75 nmol/l)
  • High risk: 31 – 50 mg/dL (75 – 125 nmol/l)
  • Very high risk: > 50 mg/dL (> 125 nmol/l)

The Treatment Challenge

Studies on the effect of diet on Lp(a) levels are limited. However, low-fat diets, in particular, seem to result in a small but significant increase in Lp(a) whereas a low-fat, high-carbohydrate diet may increase Lp(a) levels compared to a high-fat, low-carbohydrate diet.  Currently, no licenced treatments specifically target Lp(a) levels. Common cholesterol-lowering drugs like statins do not affect Lp(a) levels and might even increase them. Some evidence suggests that niacin can reduce Lp(a) levels, but it is not approved for this use, and its effectiveness in reducing cardiovascular risk remains unproven. New therapies are currently being tested in trials  for example the HORIZON phase III trial is investigating the benefit of Lp(a)-lowering with an antisense oligonucleotide (ASO), TQJ230, compared to placebo, on major cardiovascular endpoints.

Studies on the effect of diet on Lp(a) levels are limited. However, low-fat diets, in particular, seem to result in a small but significant increase in Lp(a) whereas a low-fat, high-carbohydrate diet may increase Lp(a) levels compared to a high-fat, low-carbohydrate diet. Statins can both raise and lower Lp(a)levels. Niacin decreases Lp(a) levels by approximately 20%-30% and PCSK9 inhibitors lower Lp(a) by  upto 30%. Recently, Lp(a)-specific lowering medications have become available and major ongoing clinical trials are investigating the clinical efficacy of these agents in patients with elevated Lp(a) levels: for example the HORIZON phase III trial is investigating the benefit of Lp(a)-lowering with an antisense oligonucleotide (ASO), TQJ230, compared to placebo, on major cardiovascular endpoints.

At SCVC, we now offer a database of patients with coronary heart disease that have raised LP (a), so that we can update any of those interested as soon as  new medical therapies become available. Until then, most consultants manage raised LP (a) by treating other risk factors that contribute to cardiovascular risk, such as raised LDL, unhealthy lifestyle, diets and anti inflammatory drugs such as colchicine to mitigate risk. For those found to be at apparently extremely high risk of future heart attack (discovered by undergoing a detailed CT study that includes an assessment of coronary artery inflammation (FAI)), once the subgroup affected by raised LP (a) are identified, we discuss the option of  a rescan after 2-3 years of standard preventative therapy, in order to find those we believe may be at high residual risk. These patients would be obvious candidates to offer the option of latest antisense drugs to, if and when they become generally licenced and available.

Conclusion

Lp(a) stands out as a significant, yet often overlooked player in cardiovascular health. With its significant genetic component and its ability to independently elevate cardiovascular risk, understanding and managing patients with raised Lp(a) levels is increasingly important. As research advances and new treatments are developed, the hope is that more light will be shed on this stealthy risk factor, leading to better prevention strategies and outcomes for those at risk. Awareness and education about Lp(a) are key, as they are the first steps towards tackling this hidden threat to heart health.

**In 2024 SCVC started an LP (a) register, inviting all patients with raised LP (a) to register with us, to keep updated on any news and developments in this area. To register use our enquire now form**

Further reading

  1. A call to action Lipoprotein(a) Taskforce
  2. Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
  3. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
  4. 8 Things to Know About Lipoprotein(a)
  5. Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis

  6. Non pharmacological remedies for raised LP (a), not robust but worth a look?

More articles for you

Metabolic Health Assessment

Is is increasingly obvious that not everyone with raised coronary inflammation and elevated risk of heart attack simply has a raised LDL Cholesterol- in fact there appears to be a mixed bag of risk factors associated with high coronary artery inflammation, including raised LDL, raised LP (a), raised Homocysteine, hypertension and dysregulated glucose.   Our metabolic health assessment is therefore designed to offer a comprehensive dive into known contributory causes, the latest and most controversial of which is 'glucose dysregulation', the principle topic of this article.

Five Reasons Why a Cardiologist Might Recommend a Continuous Glucose Monitor (CGM) to their Patient

Continuous glucose monitoring offers a valuable tool for anyone concerned with their long-term health, especially those with a family history of diabetes or other cardiovascular risk factors. Whether through self-monitoring or professional analysis such as our metabolic health assessment, CGMs can provide actionable insights that help individuals manage their glucose levels more effectively, ultimately contributing to a healthier, longer life. By understanding and managing your glucotype, optimising your diet and exercise, and taking steps to prevent prediabetes and diabetes, you can potentially avoid serious health conditions in the future.

What are the latest guidelines target for LDL?

For patients who have been diagnosed with an acute coronary syndrome, requiring bypass surgery or stent, or have CT Angiography and or raised FAI, the latest European and UK guidelines reflect the finding that there is no lower limit for LDL yet discovered, basically meaning the lower the better. These recommendations come after new trials with lower targets showed better outcomes. As a result, millions of people around the world need to be looking more carefully at whether they are taking sufficient medication to lower their LDL to these new targets, for the very best outcomes to be achieved.